Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia

Therapeutics and Clinical Risk Management

Volumn 3, Issue 2, 2007, Pages 269-275

  Grossi, Alberto ^a   Balestri, Francesca ^b   Santini, Simone ^c  

^a LEONARDO S P A   (Italy)

^b Blood Transfusion Center   (Italy)

^c Oncology Unit   (Italy)

Author keywords

Cancer anemia; Darbepoetin alpha; Recombinant human Epo

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM COMPLEX; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG TARGETING; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HUMAN; MULTIPLE CYCLE TREATMENT; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW; SINGLE DRUG DOSE; THROMBOEMBOLISM;

EID: 34250025879     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.2.269     Document Type: Review

References (56)

1. Alessandrino EP, Amadori S, Barosi G, et al. 2002. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica, 87:1286-306.
2. Arcasoy MO, Amin K, Chou SC, et al. 2005. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res, 11:20-7.
3. Auerbach M, Ballard H, Trout JR, et al. 2004. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol, 22:1301-7.
4. Balleari E, Rossi E, Clavio M, et al. 2006. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol, 85:174-80.
5. Beguin Y, Verna M, Loo M, et al. 1992. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol, 82:648-53.
6. Beguin Y. 1995. Erythropoiesis and erythropoietin in multiple myeloma. Leuk Lymphoma, 18:412-21.
7. Boccia R, Malik IA, Raja V, et al. 2006. Darbepoetin alpha administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist, 11:4:409-17.
8. Bohlius J, Langensiepen S, Schwarzer G, et al. 2005. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst, 97:489-98.
9. Bohlius J, Wilson J, Seidenfeld J, et al. 2006. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev, 3 :CD003407.
10. Bokemeyer C, Aapro MS, Courdi A et al. 2004. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer, 40:2201-16.
11. Bren A, Kandus A, Varl J, et al. 2002. A comparison between epoetin omega and epoetin alpha in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study, Artif Organs, 26:91-7.
12. Canon JL, Vansteenikiste J, György Bodoky G, et al. 2006. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alpha for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst, 98:273-84.
13. Cazzola M, Beguin Y, Kloczko J, et al. 2003. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol, 122:386-93.
14. Cella D. 1997. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol, 34(Suppl.2): 13-19.
15. Chang J, Couture F, Young S, et al. 2005. Weekly epoetin alpha maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol, 23:2597-605.
16. Cheson BD, Greenberg PL, Bennett JM, et al. 2006. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108:419-25.
17. Deicher R, Horl WH. 2004. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs, 64:499-509.
18. Egrie JC, Browne JK. 2001. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer, 84(Suppl. 1)3-10.
19. Elliott S, Busse L, Bass ME, et al. 2006. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood, 107:1892-5.
20. Elliott S, Egrie J, Browne J, et al. 2004. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol, 32:1146-55.
21. Gabrilove JL, Cleeland CS, Livingstone RB, et al. 2001. Clinical evaluation of once-weekly dosing of epoetin alpha in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol, 19:2875-82.
22. Glaspy J, Henry D, Patel R, et al. 2005. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alpha: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alpha, Eur J Cancer, 41:1140-9.
23. Glaspy JA, Jadeja JS, Justice G, et al. 2002. Darbepoetin alpha given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer, 87:268-76.
24. Harper P, Littlewood T. 2005. Anemia of cancer: impact on patient fatigue and long-term outcome. Oncology, 69(suppl 2):2-7.
25. Heatherington AC, Schuller J, Mercer AJ. 2001. Pharmakokinetics of novel erythropoiesis stimulating protein (NESP) in cance patients: preliminary report, Br J Cancer, 84(suppl.1):11-16.
26. Hedenus M, Adriansson M, San Miguel J, et al. 2003. Efficacy and safety of darbepoetin alpha in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol, 122:394-403.
27. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. 1998. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood, 92:68-75.
28. Henke M, Laszig R, Rube C, et al. 2003. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double-blind, placebo controlled trial. Lancet, 362:1255-60.
29. Henry DH, Gordan L, Charu V, et al. 2006. Randomized, open-label comparison of epoetin alpha extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin, 22:1403-13.
30. Herrington JD, Davidson SL, Tomita DK, et al. 2005. Utilization of darbepoetin alpha and epoetin alpha for chemotherapy-induced anemia. Am J Health Syst Pharm, 62:54-62.
31. [ICSG] Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. 1998. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol, 103:1070-4.
32. Kotasek D,Steger G, Faught W, et al. 2003. Darbepoetin alpha administered every 3 weeks alleviated anaemia in patients with solid tumors receiving chemotherapy; results of a double-blind, placebo-conrolled, randomised study. Eur J Cancer, 39:2026-34.
33. Leyland-Jones B; BEST Investigators and Study Group. 2003. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol, 4:459-60.
34. Littlewood TJ, Bajetta E, Nortier JW, et al. 2001. Epoetin alpha study group. Effects of epoetin alpha on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol, 19:2865-74.
35. Littlewood TJ, Kallich JD, San Miguel J, et al. 2006. Efficacy of darbepoetin alpha in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. J Pain Symptom Manage, 3:317-25.
36. Littlewood Ti, Zagani M, Pallister C, et al. 2003. Baseline and early treatment factors are not clinically useful for predictingindividual response to erythropoietin in anemic cancer patients. Oncologist, 8:99-107.
37. Ludwig H, Van Belle S, Barrett-Lee P, et al. 2004. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer, 40:2293-306.
38. Mannone L, Gardin C, Quarre MC, et al. 2006. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol, 133:513-19.
39. Musto P, Lanza F, Balleari E, et al. 2005. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol, 128:204-9.
40. [NCCN] National Comprehensive Cancer Network. 2006. Clinical practice guidelines in oncology, v.2.2006. Cancer and treatment-related anemia [online]. Accessed on 25 Sept 2006. URL: http:/www.enccn.com/ professionals/physician_gls/PDF/anemia.pdf.
41. Osterborg A, Brandberg Y, Molostova V, et al. 2002. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol, 20:2486-94.
42. Osterborg A, Hellmann A, Juan Luis Steegmann JL, et al. 2004. CERA (Continuous Erythropoietin Receptor Activator): Dose-response trial of subcutaneous (SC) administration once every 3 weeks (Q3W) to patients with aggressive non-Hodgkin's lymphoma and anemia receiving chemotherapy [abstract]. 46th meeting of the American Society of Hematology, December 4-7, San Diego, CA. Blood, 104:4225.
43. Patton J, Reeves T, Wallace J. 2004. Effectiveness of Darbepoetin alpha versus Epoetin alpha in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist, 9:451-8.
44. Patton JF, Sullivan T, Mun Y, et al. 2005. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alpha for epoetin alpha in anemic patients with myelodysplastic syndrome. J Support Oncol, 3:419-26.
45. Rizzo JD, Lichtin AE, Woolf SH, et al. 2002. Use of erythropoietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol, 20:4083-107.
46. Schwartzberg LS, Yee LK, Senecal FM, et al. 2004. A randomized comparison of every-2-week darbepoetin alpha and weekly epoetin alpha for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist, 9:696-707.
47. Senecal FM, Yee L, Gabrail N, et al. 2005. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alpha 200 microg every 2 weeks versus epoetin alpha 40,000 U weekly. Clin Breast Cancer, 6:446-54.
48. Shasha D, George MJ, Louis B, et al. 2003. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer, 98:1072-9.
49. Smith RE Jr, Jaiyesimi IA, Meza LA, et al. 2001. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer, 84(Suppl. 1):24-30.
50. Smith RE Jr, Tchekmedyian NS, Chan D, et al. 2003. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer, 88:1851-8.
51. Stead RB, Lambert J, Wessels O, et al. 2006. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled,dose-escalation study in healthy volunteers. Blood, 108:1830-4.
52. Terpos E, Mougiou A, Kouraklis A; The Greek MDS Study Group. 2003. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol, 118:174-80.
53. Vadhan-Raj S, Mirtsching B, Charu V, et al. 2003. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alpha every two weeks. J Support Oncol, 1:131-8.
54. Vansteenkiste J, Pirker R, Massuti B, et al., 2002. Double-blind, placebo-controlled, randomized phase iii trial of darbepoetin alpha in lung cancer patients receiving chemotherapy. J Natl Cancer Inst, 94:1211-20.
55. Waltzman R, Croot C, Justice GR, et al. 2005. Randomized comparison of epoetin alpha (40,000 U weekly) and darbepoetin alpha (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist, 10:642-50.
56. Witzig TE, Silberstein PT, Loprinzi CL, et al. 2005. Phase III, randomized, double-blind study of epoetin alpha compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol, 23:2606-17.